As of 2025-05-21, the Intrinsic Value of Brooks Laboratories Ltd (BROOKS.NS) is 54.73 INR. This BROOKS.NS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 135.00 INR, the upside of Brooks Laboratories Ltd is -59.50%.
The range of the Intrinsic Value is 40.91 - 83.21 INR
Based on its market price of 135.00 INR and our intrinsic valuation, Brooks Laboratories Ltd (BROOKS.NS) is overvalued by 59.50%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 40.91 - 83.21 | 54.73 | -59.5% |
| DCF (Growth 10y) | 67.60 - 138.75 | 90.98 | -32.6% |
| DCF (EBITDA 5y) | 67.76 - 109.84 | 80.75 | -40.2% |
| DCF (EBITDA 10y) | 91.41 - 162.11 | 114.78 | -15.0% |
| Fair Value | -34.88 - -34.88 | -34.88 | -125.84% |
| P/E | (164.24) - (208.33) | (176.17) | -230.5% |
| EV/EBITDA | 13.70 - 95.02 | 44.70 | -66.9% |
| EPV | (15.50) - (20.66) | (18.08) | -113.4% |
| DDM - Stable | (37.85) - (100.74) | (69.30) | -151.3% |
| DDM - Multi | (18.82) - (40.02) | (25.70) | -119.0% |
| Market Cap (mil) | 3,977.10 |
| Beta | 1.20 |
| Outstanding shares (mil) | 29.46 |
| Enterprise Value (mil) | 4,065.32 |
| Market risk premium | 8.31% |
| Cost of Equity | 13.57% |
| Cost of Debt | 9.75% |
| WACC | 13.49% |